Zenzedi Shortage: What Providers and Prescribers Need to Know in 2026

Zenzedi Shortage: A Provider Briefing for 2026

If you prescribe Zenzedi (dextroamphetamine sulfate) for ADHD or narcolepsy, you're likely fielding a growing number of patient calls about availability. This guide provides a comprehensive overview of the current supply landscape, what it means for your prescribing practice, and actionable resources to help your patients navigate access challenges.

Complete Timeline: How We Got Here

October 2022: FDA formally acknowledges a nationwide shortage of amphetamine mixed salts (Adderall), marking the beginning of the broader stimulant shortage. Teva Pharmaceutical (the largest generic Adderall manufacturer) reports supply constraints.

2023: Shortage expands to nearly all amphetamine-based products, including dextroamphetamine formulations. DEA production quotas are cited as a primary bottleneck. Multiple manufacturers report allocation limits from raw material suppliers.

Early 2024: Azurity Pharmaceuticals (manufacturer of Zenzedi, formerly Arbor Pharmaceuticals) issues a voluntary recall of certain Zenzedi lots due to a manufacturing quality issue. The recall further constrains an already limited supply.

Mid-2024: FDA updates shortage listings. Generic lisdexamfetamine (Vyvanse) enters the market, providing some relief for patients willing to switch to a long-acting formulation.

October 2025: DEA announces a 25% increase in aggregate production quotas for amphetamine products. This represents the most significant quota adjustment in recent years, though the effects take months to materialize as manufacturers scale production.

Early 2026: Supply is improving unevenly. High-volume products like generic Adderall see the most improvement. Niche products like brand Zenzedi remain in limited supply, with a findability score of 35/100 (frequent shortages, limited distribution).

What the Shortage Means for Your Prescribing Practice

Supply Chain Status

Zenzedi's supply chain remains constrained. As a lower-volume brand product manufactured by a single company (Azurity), it lacks the supply diversity of generic amphetamine salts. Wholesaler allocation for Zenzedi is limited or zero at many pharmacy locations, particularly chain pharmacies.

Prior Authorization Complexity

Most commercial insurers and Medicare Part D plans require prior authorization for brand-name Zenzedi, often with step therapy requiring documentation of generic dextroamphetamine trial and failure. The PA process can add 3–7 business days, during which patients may go without medication.

For patients who require the brand specifically (e.g., documented adverse reactions to generic fillers), supporting documentation strengthens the PA appeal and should include specifics about the formulation issue, not just a preference statement.

Indication-Specific Coverage

Coverage for dextroamphetamine varies by indication:

• ADHD (pediatric): Generally covered with generic step therapy
• ADHD (adult): Covered but may require additional documentation, as Zenzedi's FDA approval is technically for ages 3–16. Off-label adult use is standard practice but some plans push back.
• Narcolepsy: Covered, though some plans prefer modafinil/armodafinil as first-line

The Real-World Availability Picture

Supply Chain Mechanics

The supply chain for Zenzedi follows the standard manufacturer → wholesaler → pharmacy path, but with additional regulatory constraints:

1. DEA sets annual aggregate production quotas for dextroamphetamine
2. Azurity receives its individual manufacturing quota allocation
3. Finished product is distributed through wholesalers (McKesson, Cardinal Health, AmerisourceBergen)
4. Wholesalers allocate to pharmacies based on historical ordering patterns

The bottleneck is primarily at step 1 — the DEA quota. Even with the 25% increase, total amphetamine production capacity hasn't fully absorbed the demand spike driven by rising ADHD diagnosis rates.

Dose-Specific Variation

Some Zenzedi dose strengths are more available than others. The 10 mg and 20 mg tablets tend to be the most commonly stocked; the 2.5 mg, 7.5 mg, and 15 mg strengths are rarer. When clinically appropriate, prescribing a more common strength may improve your patient's ability to fill.

Regional Disparities

Availability varies significantly by geography. Urban areas with more pharmacy options tend to have better access, while rural patients may face longer searches. Independent pharmacies — which can source from secondary wholesalers — are often better stocked for niche products like Zenzedi.

40,089+ patients found their medications in stock

40K+

Find Zenzedi In Stock Today →

Cost and Access: The Numbers Your Patients Are Seeing

• Brand Zenzedi retail: $550–$650 for 60 tablets
• Manufacturer savings card: $75/Rx for cash-paying patients; $30/refill for eligible insured patients (savings up to $185/Rx/month, max 360 tablets/year)
• Generic dextroamphetamine with coupons: $30–$80 for 60 tablets
• With insurance (generic): $10–$50 copay (Tier 2)

Cost is a significant barrier to adherence. Patients on brand Zenzedi without adequate insurance or the manufacturer savings card face the highest burden. Proactively discussing cost during visits can prevent prescription abandonment.

Tools and Resources for Your Practice

• Medfinder Provider Portal: Search for Zenzedi availability at pharmacies on behalf of your patients. The support team contacts pharmacies directly to verify stock.
• FDA Drug Shortage Database: Monitor official shortage status at accessdata.fda.gov
• Azurity Zenzedi Savings Card: Direct patients to zenzedi.com for enrollment
• Azurity Patient Assistance Program: For uninsured/underinsured patients who meet income criteria
• NeedyMeds / RxAssist: Databases of patient assistance programs for broader coverage

Skip the calls, skip the stress.

Find Zenzedi In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Looking Ahead

Several factors may improve Zenzedi availability over the coming months:

• DEA quota effects: The October 2025 quota increase should translate to increased finished product by mid-2026 as manufacturers complete production cycles
• Stabilizing demand: The post-pandemic surge in ADHD diagnoses appears to be plateauing, which may ease overall stimulant demand
• Supply chain normalization: Wholesaler allocation systems are gradually adjusting to new demand patterns

That said, brand Zenzedi will likely remain a limited-distribution product given its niche status. Providers should continue planning for potential access challenges.

Final Thoughts

As prescribers, you play a critical role in helping patients navigate the Zenzedi shortage:

1. Use the Medfinder provider portal to locate Zenzedi for patients
2. Consider prescribing common dose strengths (10 mg, 20 mg) when clinically appropriate
3. Discuss cost and savings programs proactively — the manufacturer card can reduce brand cost to $75/Rx
4. Have a backup plan: generic dextroamphetamine, Adderall, or Vyvanse may be more available
5. Direct patients to the patient-facing shortage update for self-help resources

For more provider resources:

• How to Help Your Patients Find Zenzedi in Stock: A Provider's Guide
• How to Help Your Patients Save Money on Zenzedi